文献速递心力衰竭与心肌病

秋水仙碱在急性失代偿性心力衰竭中的随机对照试验:COLICA研究

Colchicine in acutely decompensated heart failure: the COLICA trial.
PubMed 文献 · Eur Heart J · 2024-01-01

COLICA试验为多中心、随机、双盲、安慰剂对照研究,纳入278例急性心力衰竭患者,随机接受秋水仙碱或安慰剂治疗8周。结果显示两组NT-proBNP时间平均下降无差异,但秋水仙碱显著降低炎症标志物且安全性可接受。

要点

  • 秋水仙碱未显著降低急性心衰患者8周NT-proBNP水平。
  • 秋水仙碱显著降低CRP和IL-6,且不增加停药率。
  • 秋水仙碱组随访期间静脉呋塞米需求较低,但恶化性心衰事件无差异。

核心结论

  • 秋水仙碱在急性心衰患者中安全且有效减轻炎症,但在降低NT-proBNP和预防新发恶化心衰事件方面与安慰剂效果相当。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照试验,纳入278例急性心衰患者,随机分为秋水仙碱组(n=141)和安慰剂组(n=137)。
  • 患者需接受≥40 mg静脉呋塞米,不限左室射血分数(LVEF)和住院或门诊状态,随机于就诊24小时内进行。
  • 秋水仙碱负荷剂量2 mg,随后0.5 mg每12小时一次,持续8周。

主要发现

  • 主要终点8周NT-proBNP时间平均下降率:秋水仙碱组-62.2%(95%CI -68.9%至-54.2%),安慰剂组-62.1%(95%CI -68.6%至-54.3%),变化比值为1.0。
  • 腹泻在秋水仙碱组稍常见,但停药率无差异(8.5% vs 8.8%)。

临床怎么用

  • 对于急性心衰患者,秋水仙碱可考虑用于减轻炎症反应,但不应期望其改善NT-proBNP或减少恶化心衰事件。
  • 使用秋水仙碱时需关注腹泻不良反应,但停药率与安慰剂相当。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Acute heart failure (AHF) promotes inflammatory activation, which is associated with worse outcomes. Colchicine has proven effective in other cardiovascular conditions characterized by inflammatory activation, but has never been evaluated in the setting of AHF. METHODS: This multicenter, randomized, double-blind, and placebo-controlled trial included patients with AHF, requiring ≥40 mg of intravenous furosemide, regardless of their left ventricular ejection fraction (LVEF) and inpatient or outpatient setting. Patients were randomized within the first 24 h of presentation to receive either colchicine or placebo, with loading dose of 2 mg, followed by 0.5 mg every 12 h for 8 weeks. RESULTS: A total of 278 patients [median age 75 years, LVEF 40%, baseline N-terminal pro-B-type natriuretic peptide (NT-proBNP) 4262 pg/mL] were randomized to colchicine (n = 141) or placebo (n = 137). The primary endpoint, the time-averaged reduction in NT-proBNP levels at 8 weeks, did not differ between the colchicine group [-62.2%, 95% confidence interval (CI) -68.9% to -54.2%] and the placebo group (-62.1%, 95% CI -68.6% to -54.3%) (ratio of change 1.0). The reduction in inflammatory markers was significantly greater with colchicine: ratio of change 0.60 (P < .001) for C-reactive protein and 0.72 (P = .019) for interleukin-6. No differences were found in new worsening heart failure episodes (14.9% with colchicine vs. 16.8% with placebo, P = .698); however, the need for intravenous furosemide during follow-up was lower with colchicine (P = .043). Diarrhea was slightly more common with colchicine, but it did not result in differences in medication withdrawal (8.5% vs. 8.8%). CONCLUSIONS: Colchicine was safe and effective in reducing inflammation in patients with AHF; however, colchicine and placebo exhibited comparable effects on reducing NT-proBNP and preventing new worsening heart failure events.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Pascual-Figal, Núñez, Pérez-Martínez, et al. Colchicine in acutely decompensated heart failure: the COLICA trial. Eur Heart J. 2024. PMID: 39211951. doi:10.1093/eurheartj/ehae538

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。